Sequelae of cardiopulmonary bypass-induced pulmonary injury

Patent metadata

Field	Value
Publication number	US-10265286-B2
Application number	US-201715853248-A
Country	US
Kind code	B2
Filing date	Dec 22, 2017
Priority date	Dec 28, 2016
Publication date	Apr 23, 2019
Grant date	Apr 23, 2019

Abstract

A method for administering citrulline to a patient during surgery without filtration of the hemolysis to reduce the uncoupling of eNOS enzyme dimer that leads to cardiopulmonary bypass-induced pulmonary injury.

First claim

What is claimed is:

1. A method for maintaining the coupling of endothelial nitric oxide synthase (eNOS) to reduce the incidence or severity of cardiopulmonary bypass-induced pulmonary injury due to free radical formation in a patient during cardiopulmonary bypass comprising administering an effective amount of citrulline to the patient before, during, and after the surgery, wherein the citrulline administered at the initiation of the surgery is about 100-500 mg/kg of citrulline,
wherein the citrulline administered during the surgery is added to hemoconcentration replacement fluid during the surgery,
wherein the effective amount of citrulline is an amount sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS).

2. The method of claim 1 , wherein the effective amount of citrulline is an amount sufficient to reduce the formation of free radicals.

3. The method of claim 1 , wherein the effective amount of citrulline is an amount sufficient to reduce the incidence or severity of cardiopulmonary bypass-induced pulmonary injury.

4. The method of claim 1 , wherein the citrulline is administered prior to the surgery is administered at about 12 hours prior to the surgery.

5. The method of claim 1 , wherein the surgery is to correct a cardiac defect.

6. The method of claim 1 , wherein the citrulline added during the surgery is added at about 100-500 μmol/L.

7. The method of claim 1 , wherein citrulline is administered after the surgery is administered to the patient for about 12-48 hours after surgery at about 3-12 mg/kg/hour.

8. The method of claim 1 , wherein the citrulline is administered orally, intravenously, by inhalation, or a combination thereof.

9. The method of claim 1 , wherein the patient's plasma citrulline level is raised above 100 μmol/L.

10. The method of claim 1 , wherein the patient's plasma citrulline level is raised above about 100 μmol/L postoperatively.

11. The method of claim 1 , wherein the patient is a neonate, pre-adolescent, adolescent, or an adult.

12. The method of claim 1 , wherein the patient is a preterm infant.

13. The method of claim 1 , wherein the patient's intensive care unit (ICU) stay is decreased.

14. The method of claim 1 , wherein the patient's intensive care unit (ICU) stay is decreased to less than 27 days.

Assignees

• Univ Vanderbilt

Inventors

• Summar Marshall L
• Barr Frederick W

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P41/00

  Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution · CPC title

• A61P39/06

  Free radical scavengers or antioxidants · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title